Abstract:OBJECTIVE To investigate the efficacy and side effects of mycophenolate mofetil (MMF) in the treatment of diffuse proliferative lupus nephritis( DPLN). METHODS 75 patients [13 male,62 female; age (31.0 +/- 10.1)y] with biopsy-proven active DPLN from nine hospitals in China from Jan. 1999 to Jan. 2000 were enrolled in this study, of whom 26 patients were refractory to conventional treatment of steroids and cyclophosphamide. 21 patients presented with relapses and 28 patients were newly diagnosed. All the patients were treated with a combined regimen of MMF and steroids. Patients who had severe active renal lesions were initially given intravenous methylprednisolone followed by oral prednisone. The initial dosage of MMF was 0.5 approximately 2.0 g/d and the administrati on maintained at least 6 months. 38 patients had repeat renal biopsy after treatment. SLE disease activity (SLE-DAI) score, renal active index (AI),chronic index(CI) and density of immunoglobulins, complement deposition was assessed before and after MMF treatment. RESULTS The mean starting dosage of MMF was (1.26 +/- 0.30) g/d, it was reduced to (1.21 +/- 0.30) g/d and (0.95 +/- 0.33) g/d at the end of the 3(rd) and 6(th) month respectively. The post-treatment Hb level increased from (92 +/- 21) g/L to (112 +/- 28) g/L(3 mo) and (116 +/- 21) g/L(6 mo), while proteinuria decreased from (4.24 +/- 2.66) g/d to (2.18 +/- 3.75) g/d (3 mos, P < 0.05) and (1.54 +/- 1.60) g/d( 6 mos,P < 0.01). Renal function impairment present in some of the patients also showed marked improvement. The proportion of patients with positive A-dsDNA antibody and hypocomplementemia was significantly reduced after 6 months of MMF treatment. SLE-DAI score in this group of patients decreased from (16.9 +/- 6.7) to (8.1 +/- 4.8) (P < 0.01) by the end of 3 months. Repeat renal biopsy in 38 patients 3 approximately 6 months after the treatment showed a significant decrement of AI ( 13.30 +/- 5.51) vs (3.38 +/- 1.98),P < 0.01, and an increment of CI (1.62 +/- 1.48) vs (2.62 +/- 1.85), P > 0.05. Immunoglobulins and complement deposition scores decreased from (9.39 +/- 3.51) to(6.71 +/- 3.16 ),P < 0.05. During the study period, 12 episodes of infection (16.0%) were recorded including pneumonia(2.7%), herpes zoster(8.0 %), urinary tract infection(2.7%), and tuberculosis(2.7%). Other side effects included gastrointestinal symptoms (10.7%), hirsutism(6.7%), leukocytopenia (1.3%) and transient elevation of SGPT(2.7%). CONCLUSION MMF in a dosage of 0.5 approximately 2.0 g/d combined with steroids is effective to control the lupus activity of DPLN and well tolerated by the patients.

Prospective-controlled trial of Mycophenolate mofetil in patients with exacerbating chronic hepatitis B of severe degree

Prediction Value of Model for End-Stage Liver Disease Scoring System on Prognosis in the Acute on Chronic Liver Failure Patients with Plasma Exchange Treatment.

Mycophenolate mofetil combined with low dose prednisone in the treatment for adults with minimal change nephrotic syndrome and concomitant HBsAg positive

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Mycophenolate Sodium Enteric-Coated Tablets Versus Mycophenolate Mofetil for Inhibition of Bone Marrow in Renal Transplant Repicients

Clinical Study of Mycophenolate Mofetil Combined with Interferon-α Treating Children with Refractory HBV-associated Nephritis

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Effects Of Mycophenolate Mofetil Combined With Corticosteroids For Induction Therapy Of Microscopic Polyangiitis

A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.

Comparison of EB virus infection between short term and long term use of mycophenolate mofetil for prophylaxis of graft versus host disease after haploidentical hematopoietic stem cell transplantation

The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial

[Mycophenolate Mofetil in Treatment of Graft-Versus-host Disease after Allogeneic Hematopoietic Cell Transplantation: Analysis of 44 Cases].

Efficacy and long-term prognosis of mycophenolate mofetil treatment on patients with proliferative lupus nephritis

[Clinical Research of Plasma Exchange with Continuous Veno-Venous Hemofiltration in Treating Mid- and Late-Stage Chronic Severe Viral Hepatitis B Patients].

Promoting Hepatic Growth Factor in the Treatment of Heavy Type Hepatitis and Severe Chronic Hepatitis: a Multicenter Clinical Study.

Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure

Impact of Mycophenolate Mofetil Prophylaxis Duration on Acute Graft-Versus-host Disease after Haploidentical Stem Cell Transplantation

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

Mycophenolate Mofetil Treatment for Diffuse Proliferative Lupus Nephritis: a Multicenter Clinical Trial in China.

Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome.

A study of therapeutic efficacy of mycophenolate mofetil in the treatment of multiple sclerosis ;and neuromyelitis optica